Phase II testing of sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND. 182-185

Current Oncology

Volumn 14, Issue 4, 2007, Pages 154-161

  Buckstein, Rena ^a   Meyer, R M ^b   Seymour, L ^b   Biagi, J ^c   MacKay, H ^d   Laurie, S ^e   Eisenhauer, E ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c Cancer Centre of Southeastern Ontario   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Angiogenesis; IND; NCIC; Phase II; Receptor tyrosine kinase inhibitor; Sunitinib

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; BEPRIDIL; BEVACIZUMAB; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISOPYRAMIDE; DOXORUBICIN; IFOSFAMIDE; KETOCONAZOLE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PREDNISONE; PROBUCOL; PROCAINAMIDE; QUINIDINE; RIFAMPICIN; RITUXIMAB; SOTALOL; SUNITINIB; TAXANE DERIVATIVE; TERFENADINE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG HEMORRHAGE; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAPANICOLAOU TEST; PERITONEUM CANCER; PLEURA MESOTHELIOMA; QT PROLONGATION; RECURRENT CANCER; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKIN DISCOLORATION; SOLID TUMOR; STEM CELL TRANSPLANTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TORSADE DES POINTES; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; VOMITING;

EID: 42049098575     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.132     Document Type: Article

References (60)

1. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96.
2. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controiled trial. Lancet 2006;368:1329-38.
3. Fiedler W, Serve H, Döhner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
5. Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 2004;21:107-18.
6. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
7. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
8. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002;29(suppl 6):18-22.
9. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-8.
10. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992;80:2142-8.
11. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;32:673-9.
12. Helsing MD. Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Eur J Cancer 1997;33:500-2.
13. El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW. VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma. Int J Oncol 2000;16:777-82.
14. Osby E, Liliemark F, Bjorkholm M, Liliemark J. Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study. Med Oncol 2001;18:269-75.
15. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999;106:504-9.
16. Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000;28:993-1000.
17. Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005;17:611-16.
18. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-902.
19. Bertolini F, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000;96:282-7.
20. Stopeck A, Bellamy WT, Unger J, et al. Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108 [abstract 6592]. Proc Am Soc Clin Oncol 2005;23.
21. Buckstein R, Kerbel RS, Shaked Y, et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12(suppl 5):5190-8.
22. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2004. Toronto: Canadian Cancer Society; 2004. [Available online at: www.cancer.ca/vgn/images/portal/cit_86751114/14/33/ 195986411niw_stats2004_en.pdf; cited April 2004]
23. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004;159:107-12.
24. König JE, Tolnay E, Wiethege T, Müller KM. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 1999;435:8-12.
25. Ohta Y, Shridhar V, Bright RX, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61.
26. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75.
27. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003;104;683-10.
28. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda: National Cancer Institute; 2003.
29. Fyles AW, Pintilie M, Kirkbride P, Levin W, Manchul LA, Rawlings GA. Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother Oncol 1995;35:107-17.
30. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-33.
31. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-85.
32. Omura GA. Chemotherapy for cervix cancer. Semin Oncol 1994;21:54-62.
33. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996;14:792-5.
34. Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993;168:805-7.
35. Muderspach LI, Blessing JA, Levenback C, Moore IL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001;81:213-15.
36. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 2002;85:469-75.
37. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K, Sekiya S. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005;103:724-30.
38. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
39. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [full report, online update]. Practice guideline report 4-1-2. Toronto: Cancer Care Ontario; 2004. [Available online at: www.cancercare.on.ca/pdf/pebc4-1-2f.pdf; cited June 2004]
40. Thigpen T, Stuart G, du Bois A, et al. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 2005;16(suppl 8):viii13-19.
41. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
42. Parmar MK, Ledermann JA, Colombo, N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the IC0N4/ AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
43. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol. Pathol 2002;55:348-59.
44. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-7.
45. Teramoto H, Castellone MD, Malek RL, et al. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 2005;24:489-501.
46. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovanan cancer. Gynecol Oncol 2005;96:902-5.
47. Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOC) study. Proc Am Soc Clin Oncol 2005;23:457s.
48. Garcia AA, Oza A, Hirte H, et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial. Proc Am Soc Clin Oncol 2005;23:455s.
49. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-60.
50. Rosen L, Mulay M, Long J, et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract 765]. Proc Am Soc Clin Oncol 2003;22:191.
51. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
52. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
53. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61.
54. Auerbach R, Akhtar N, Lewis RL, Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000;19:167-72.
55. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;64341-4.
56. Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003;522:83-97.
57. Cortelezzi A, Fracchiolla NS, Mazzeo LM, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma 2005;46:1345-51.
58. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.
59. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003;9:377-82.
60. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7.